223 related articles for article (PubMed ID: 36860854)
1. Advances in preventive vaccine development against HTLV-1 infection: A systematic review of the last 35 years.
Santana CS; Andrade FO; da Silva GCS; Nascimento JOS; Campos RF; Giovanetti M; Santos LA; Gois LL; Alcantara LCJ; Barreto FK
Front Immunol; 2023; 14():1073779. PubMed ID: 36860854
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. How do socioeconomic determinants of health affect the likelihood of living with HTLV-1 globally? A systematic review with meta-analysis.
Ramesh N; Cockbain B; Taylor GP; Rosadas C
Front Public Health; 2024; 12():1298308. PubMed ID: 38327581
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Laboratory Outcomes in HIV-1 and HTLV-1/2 Coinfection: A Systematic Review.
Montaño-Castellón I; Marconi CSC; Saffe C; Brites C
Front Public Health; 2022; 10():820727. PubMed ID: 35359787
[TBL] [Abstract][Full Text] [Related]
5. An overview of sequencing technology platforms applied to HTLV-1 studies: a systematic review.
de Oliveira Andrade F; Cucco MS; Borba MMN; Neto RC; Gois LL; de Almeida Rego FF; Santos LA; Barreto FK
Arch Virol; 2021 Nov; 166(11):3037-3048. PubMed ID: 34415436
[TBL] [Abstract][Full Text] [Related]
6. Prevention of human T-cell lymphotropic virus type 1 infection and adult T-cell leukemia/lymphoma.
Yoshimitsu M; White Y; Arima N
Recent Results Cancer Res; 2014; 193():211-25. PubMed ID: 24008301
[TBL] [Abstract][Full Text] [Related]
7. Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies.
Seighali N; Shafiee A; Rafiee MA; Aminzade D; Mozhgani SH
BMC Infect Dis; 2023 May; 23(1):320. PubMed ID: 37170214
[TBL] [Abstract][Full Text] [Related]
8. 40 years of the human T-cell leukemia virus: past, present, and future.
Tagaya Y; Matsuoka M; Gallo R
F1000Res; 2019; 8():. PubMed ID: 30854194
[TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
10. Population-based prevalence of human T-lymphotropic virus type 1 in sub-Saharan Africa: a systematic review and meta-analysis.
Ngoma AM; Omokoko MD; Mutombo PB; Mvika ES; Muwonga JM; Nollet KE; Ohto H
Trop Med Int Health; 2019 Nov; 24(11):1277-1290. PubMed ID: 31465629
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.
Legrand N; McGregor S; Bull R; Bajis S; Valencia BM; Ronnachit A; Einsiedel L; Gessain A; Kaldor J; Martinello M
Clin Microbiol Rev; 2022 Apr; 35(2):e0007821. PubMed ID: 35195446
[TBL] [Abstract][Full Text] [Related]
12. Reducing the global burden of HTLV-1 infection: An agenda for research and action.
Willems L; Hasegawa H; Accolla R; Bangham C; Bazarbachi A; Bertazzoni U; Carneiro-Proietti AB; Cheng H; Chieco-Bianchi L; Ciminale V; Coelho-Dos-Reis J; Esparza J; Gallo RC; Gessain A; Gotuzzo E; Hall W; Harford J; Hermine O; Jacobson S; Macchi B; Macpherson C; Mahieux R; Matsuoka M; Murphy E; Peloponese JM; Simon V; Tagaya Y; Taylor GP; Watanabe T; Yamano Y
Antiviral Res; 2017 Jan; 137():41-48. PubMed ID: 27840202
[TBL] [Abstract][Full Text] [Related]
13. HTLV-I induces lesions in the pulmonary system: A systematic review.
Normando VMF; Dias ÁRN; da Silva ALSE; da Silva Pinto D; de Souza Santos MC; Rodrigues CL; de Oliveira EM; de Souza Filho LEC; de Brito Vieira W; Andriolo RB; Sousa RCM; Falcão LFM; Quaresma JAS
Life Sci; 2020 Sep; 256():117979. PubMed ID: 32553930
[TBL] [Abstract][Full Text] [Related]
14. Current status of HTLV-1 infection.
Watanabe T
Int J Hematol; 2011 Nov; 94(5):430-4. PubMed ID: 21969187
[TBL] [Abstract][Full Text] [Related]
15. [Human T-lymphotropic virus type I (HTLV-I): risk of transmission with transfusion].
Lefrère JJ
Presse Med; 2000 Jun; 29(20):1134-8. PubMed ID: 10901796
[TBL] [Abstract][Full Text] [Related]
16. Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications.
Jørgensen L; Gøtzsche PC; Jefferson T
Syst Rev; 2020 Feb; 9(1):42. PubMed ID: 32106871
[TBL] [Abstract][Full Text] [Related]
17. Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits.
Franchini G; Tartaglia J; Markham P; Benson J; Fullen J; Wills M; Arp J; Dekaban G; Paoletti E; Gallo RC
AIDS Res Hum Retroviruses; 1995 Feb; 11(2):307-13. PubMed ID: 7742044
[TBL] [Abstract][Full Text] [Related]
18. Human T cell lymphotropic virus: necessity for and feasibility of a vaccine.
de Thé G; Bomford R; Kazanji M; Ibrahim F
Ciba Found Symp; 1994; 187():47-55; discussion 55-60. PubMed ID: 7796676
[TBL] [Abstract][Full Text] [Related]
19. HTLV-1 and leukemogenesis: virus-cell interactions in the development of adult T-cell leukemia.
Zane L; Jeang KT
Recent Results Cancer Res; 2014; 193():191-210. PubMed ID: 24008300
[TBL] [Abstract][Full Text] [Related]
20. An HTLV-I vaccine: why, how, for whom?
de Thé G; Bomford R
AIDS Res Hum Retroviruses; 1993 May; 9(5):381-6. PubMed ID: 8318266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
